Loading clinical trials...
Loading clinical trials...
A Two Part Phase I, Multiple-dose, Single- and Double-blind, Randomised, Double-dummy, Placebo-controlled, Four-way Crossover Study to Assess Safety and Tolerability of BI 443651 Via Respimat® Versus Placebo Via Respimat® in Subjects With Mild Asthma Following Methacholine Challenge.
Conditions
Interventions
BI 443651
Placebo
Locations
1
United Kingdom
The Medicines Evaluation Unit
Manchester, United Kingdom
Start Date
May 18, 2017
Primary Completion Date
February 7, 2018
Completion Date
February 21, 2018
Last Updated
November 27, 2019
NCT02327897
NCT07219173
NCT07486401
NCT04706988
NCT04639791
NCT06471257
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions